Browse Category

NYSE:TRP News 3 December 2025

TC Energy (TRP) Stock on December 3, 2025: Latest News, Dividend Yield and 2028 Growth Forecast

TC Energy (TRP) Stock on December 3, 2025: Latest News, Dividend Yield and 2028 Growth Forecast

TC Energy Corporation (TSX: TRP, NYSE: TRP) remains in the spotlight on December 3, 2025, as investors digest fresh Q3 results, a reaffirmed multi‑year growth outlook, a rich dividend stream and a stream of new analyst and institutional activity around the stock. On the New York Stock Exchange, TC Energy shares closed at $53.80 on December 2, 2025, implying a market capitalization of about $53.78 billion and a roughly 7% increase in market value over the past year.StockAnalysis On the Toronto Stock Exchange, the Canadian listing (TRP.TO) last traded at C$75.24 on December 2, slipping 0.9% on the day but

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop